Why I Hate AstraZeneca plc

Aside from its 5.6% yield, Harvey Jones finds little to love about AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There is something to love and hate in almost every stock, but sometimes the hate outweighs the love. Today, that’s the case with AstraZeneca (LSE: AZN) (NYSE: AZN.US). Here are five reasons why.

Where did the growth go? 

If you had invested in AstraZeneca three years ago, you would now be sitting on a loss of nearly 5%. In that time, the FTSE 100 rose 15% and pharmaceutical rival GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) was up a healthy 22%. That’s serious underperformance by AZN. The slide has continued with a 6% fall in the past six months, against a 5% rise on the FTSE 100. Reversing this will take time.

Too much bad news

Most companies like to bury the bad news in their results. AstraZeneca doesn’t have that luxury. Its recent results headlined a 4% drop in Q2 revenue to $6.23 billion, largely due to loss of exclusivity on several key brands, which wiped out around $500 billion of revenue. Core operating profit was down 10% to $2.06 billion, while core earnings per share (EPS) fell 21% to $1.20. Pricing pressure in Europe hasn’t helped, either. You can praise management for its honesty, if little else.

It’s a long road to recovery

Pascal Soriot, chief executive officer, has put on a brave face, claiming “real progress” against AZN’s strategic priorities, with its investment in distinctive science, pipeline projects and key markets delivering double-digit revenue growth. Bringing new prescription drugs to market is a precarious business, with many a slip between pipeline and profit. As a pure pharmaceuticals group, without the diversification that Glaxo’s consumer healthcare division gives it, AstraZeneca has to get this right.

This stock is all yield

One of the benefits of a falling share price is a rising yield, so you won’t be surprised to see that AstraZeneca now yields a highly likeable 5.6%, against Glaxo’s 4.7%. But what I don’t like is that the first interim dividend was exactly the same as last year. No progression there. Management also decided there would be no share repurchases this year, claiming it can put the money to better use by investing in the business. Let’s hope so.

Growth still looks scarce

AstraZeneca is on a forecast 21% drop in earnings per share (EPS) this calendar year. 2014 should see a smaller fall of 6%, but that’s still a fall. Throw in a 12% drop in 2012, and EPS look set to fall across three consecutive years. The result is that you can buy AZN at just 7.8 times earnings, almost half Glaxo’s valuation of 14 times earnings. AstraZeneca may suit patient contrarians, but these embarrassing figures show just how far it has fallen behind its big rival in recent years.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Harvey owns shares in GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

 
 

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »